Kairasec

Candesartan Cilexetil, the active ingredient in Kairasec, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and to support treatment of heart failure in adult patients.

GNH USA supplies Kairasec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards, is manufactured under strict regulatory oversight, and its consistent quality enables reliable therapeutic outcomes across diverse healthcare settings.

Kairasec, an angiotensin II receptor blocker, is used in cardiovascular conditions that involve the renin‑angiotensin system. - Hypertension: reduces systemic vascular resistance and lowers elevated blood pressure. - Heart failure: improves cardiac function, decreases symptoms, and reduces risk of hospitalization. - Left ventricular dysfunction after myocardial infarction: helps prevent adverse remodeling and supports recovery. - Chronic kidney disease with proteinuria: slows progression of renal impairment.

Candesartan may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Abdominal discomfort - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Hyperkalemia - Acute kidney injury - Liver enzyme elevation

When prescribing candesartan, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood pressure: adjust therapy if hypotension occurs. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum electrolytes: especially potassium levels. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid use during pregnancy unless clearly indicated: potential fetal risk. - Store below 25°C: keep in the original pack, protect from moisture.

Candesartan can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - ACE inhibitors or other ARBs: risk of additive hypotension and renal dysfunction. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect and affect renal function. - Thiazide diuretics: may enhance hypotensive response. - CYP450 inhibitors (e.g., ketoconazole): can raise candesartan plasma concentrations. - Antidiabetic agents: monitor glucose control as blood pressure changes may affect glycemic levels.